Wall Street brokerages expect Steris PLC (NYSE:STE) to post earnings per share (EPS) of $1.26 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Steris’ earnings, with the highest EPS estimate coming in at $1.30 and the lowest estimate coming in at $1.23. Steris posted earnings per share of $1.12 during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.5%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 6th.
According to Zacks, analysts expect that Steris will report full-year earnings of $4.78 per share for the current financial year, with EPS estimates ranging from $4.74 to $4.80. For the next financial year, analysts expect that the company will post earnings of $5.34 per share, with EPS estimates ranging from $5.25 to $5.52. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Steris.
Steris (NYSE:STE) last posted its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported $1.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.02. Steris had a net margin of 11.72% and a return on equity of 12.15%. The firm had revenue of $679.00 million for the quarter, compared to the consensus estimate of $659.14 million. During the same quarter in the prior year, the company posted $0.94 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year.
Several equities research analysts have commented on STE shares. Sidoti upped their price objective on Steris from $155.00 to $157.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Investment Research reiterated a “buy” rating and set a $132.00 target price on shares of Steris in a research report on Friday, November 16th. Finally, KeyCorp increased their target price on Steris from $120.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $124.71.
In other Steris news, insider Michael J. Tokich sold 34,500 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $119.16, for a total value of $4,111,020.00. Following the transaction, the insider now owns 64,958 shares in the company, valued at approximately $7,740,395.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $120.50, for a total value of $1,205,000.00. The disclosure for this sale can be found here. Company insiders own 2.38% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Great West Life Assurance Co. Can lifted its holdings in Steris by 0.5% in the 2nd quarter. Great West Life Assurance Co. Can now owns 137,263 shares of the medical equipment provider’s stock valued at $14,452,000 after purchasing an additional 697 shares in the last quarter. Sigma Investment Counselors Inc. acquired a new stake in shares of Steris in the 3rd quarter worth $223,000. Northern Trust Corp increased its stake in shares of Steris by 0.7% in the 2nd quarter. Northern Trust Corp now owns 643,608 shares of the medical equipment provider’s stock worth $67,585,000 after acquiring an additional 4,623 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Steris in the 2nd quarter worth $557,000. Finally, Beaumont Financial Partners LLC acquired a new stake in shares of Steris in the 3rd quarter worth $212,000. Institutional investors own 88.35% of the company’s stock.
Shares of NYSE:STE opened at $113.94 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.01 and a current ratio of 2.63. Steris has a twelve month low of $82.88 and a twelve month high of $121.67. The company has a market capitalization of $10.07 billion, a P/E ratio of 27.46 and a beta of 1.05.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 21st. Stockholders of record on Wednesday, November 28th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Tuesday, November 27th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.19%. Steris’s dividend payout ratio (DPR) is 32.77%.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Further Reading: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.